Cited by 239Sleep and related disordersObstructive Sleep Apnea ResearchSleep and Work-Related Fatigue

Nightly treatment of primary insomnia with eszopiclone for six months: effect on sleep, quality of life, and work limitations

Open access
Walsh, James K., Krystal, Andrew D., Amato, David A., Rubens, Robert, Caron, Judy, Wessel, Thomas C., Schaefer, Kendyl, Roach, James +2 more·2007·Sleep

Abstract

STUDY OBJECTIVES: To evaluate 6 months' eszopiclone treatment upon patient-reported sleep, fatigue and sleepiness, insomnia severity, quality of life, and work limitations. DESIGN: Randomized, double blind, controlled clinical trial. SETTING: 54 research sites in the U.S. PATIENTS: 830 primary insomnia patients who reported mean nightly total sleep time (TST) < or = 6.5 hours/night and/or mean nightly sleep latency (SL) >30 min. INTERVENTION: Eszopiclone 3 mg or matching placebo. MEASUREMENTS: Patient-reported sleep measures, Insomnia Severity Index, Medical Outcomes Study Short-Form Health Survey (SF-36), Work Limitations Questionnaire, and other assessments measured during baseline, treatment Months 1-6, and 2 weeks following discontinuation of treatment. RESULTS: Patient-reported sleep and daytime function were improved more with eszopiclone than with placebo at all months (P <0.001). Eszopiclone reduced Insomnia Severity Index scores to below clinically meaningful levels for 50% of patients (vs 19% with placebo; P <0.05) at Month 6. SF-36 domains of Physical Functioning, Vitality, and Social Functioning were improved with eszopiclone vs placebo for the Month 1-6 average (P < 0.05). Similarly, improvements were observed for all domains of the Work Limitations Questionnaire with eszopiclone vs placebo for the Month 1-6 average (P <0.05). CONCLUSIONS: This is the first placebo-controlled investigation to demonstrate that long-term nightly pharmacologic treatment of primary insomnia with any hypnotic enhanced quality of life, reduced work limitations, and reduced global insomnia severity, in addition to improving patient-reported sleep variables.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/sleep/30.8.959

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 2

  1. American Psychiatric Association. Sleep disorders. In: Diagnostic and statistical manual of mental disorders. 4 th ed. Washington, DC: American Psychiatric Publishing; 1994:597-661
  2. Leger D, Massuel MA, Metlaine A; SISYPHE Study Group. Profes- sional correlates of insomnia. Sleep 2006;29:171-8.

Cited by

Sorted by citations

Authors
Walsh, J. K., Krystal, A. D., Amato, D. A., Rubens, R., Caron, J., Wessel, T. C., Schaefer, K., Roach, J., Wallenstein, G., & Roth, T.
Affiliations
  • Saint Louis University (US)
  • Duke Medical Center (US)
  • Sunovion (United States) (US)
  • Henry Ford Hospital (US)
Corresponding author
Walsh, James K.
Venue
Sleep
Published
2007-08
Volume
30
Issue
8
Pages
959-968
ISSN
  • 0161-8105 (ISSN-L)
  • 1550-9109
OpenAlex
W2127024218
Cited by
239
References
30
Citations by year
2026: 9 · 2025: 5 · 2024: 8 · 2023: 4 · 2022: 5 · 2021: 10 · 2020: 10 · 2019: 8 · 2018: 9 · 2017: 8 · 2016: 16 · 2015: 11 · 2014: 13 · 2013: 11 · 2012: 20
FWCI
32.41
Type
journal article
Language
en
Open access
Locations
  • SLEEP (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Eli Lilly and Company
  • Pfizer
  • GlaxoSmithKline
  • Sanofi
  • Neurocrine Biosciences
  • National Institutes of Health
Topics
  • Social Sciences › Psychology › Experimental and Cognitive Psychology › Sleep and related disorders
  • Health Sciences › Medicine › Physiology › Obstructive Sleep Apnea Research
  • Social Sciences › Psychology › Experimental and Cognitive Psychology › Sleep and Work-Related Fatigue
Keywords
eszopiclone, primary insomnia, sleep quality, quality of life, work limitations, insomnia severity, daytime fatigue, sleep latency, total sleep time, patient-reported outcomes
MeSH terms
Adult, Arousal, Double-Blind Method, Female, Humans, Hypnotics and Sedatives, Sleep Initiation and Maintenance Disorders, Long-Term Care, Male, Middle Aged, Piperazines, Quality of Life, Social Adjustment, Wakefulness, Work Capacity Evaluation, Azabicyclo Compounds

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review